BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Deals

  Pfizer Quietly Takes Additional Stake in This Boston Pharma

  Pfizer has increased its stake in Rhythm Pharmaceuticals.

  October 19, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Arcturus Rockets on New Hep B RNA Deal With Johnson & Johnson

  Shares of Arcturus are up nearly 15 percent in Thursday morning trading after the company inked a collaboration agreement with Janssen Pharma to develop a hepatitis B drug program.

  October 19, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Bay Area’s Intuitive Surgical Buys NC Facility Very Close to Rival TransEnterix

  The new acquisition joins a smaller facility Intuitive has in the region at N.C. State University’s Centennial Campus.

  October 19, 2017

   · 

  1 min read
• 

  FDA

  Novartis Has Set a Tricky Precedent in Gene Therapy

  A look at how the gene therapy approvals may end up confusing payers, lawmakers, and the general public at a time when the industry desperately needs clarity.

  October 19, 2017

   · 

  5 min read

   · 

  Karl Thiel
• 

  Drug Development

  DURECT Stock Plunges as Pain Med Fails Phase III

  DURECT’s Posimir (SABER - Bupivacaine) for post-surgical pain failed its Phase III clinical trial.

  October 19, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Job Trends

  Pfizer Gets Incentives to Keep a 250 Employee Workforce in Memphis

  About 250 Pfizer employees will remain in the Memphis area after the pharma giant secured a partial tax freeze for 14 years from local governments that will save the company an estimated $5.3M in taxes.

  October 19, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  FDA

  Eli Lilly Looks Over Its Shoulder After Novo Nordisk Wins FDA Panel Backing for Diabetes Drug

  An advisory panel with the FDA gave a near unanimous support to Novo Nordisk’s diabetes drug semaglutide, a long-acting GLP-1 analogue.

  October 19, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  BioMidwest

  Here is the One Biotech Billionaire Investors Love

  WalletHub recently examined the quarterly filings of hedge funds to determine which stocks they’re buying the most.

  October 19, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Policy

  FDA Slaps Warning Letters on Two Medical Device Manufacturers

  The federal watchdog said it was responding to a letter it received from Director Dr. Mark Smith at Kelyniam in June.

  October 19, 2017

   · 

  1 min read
• 

  BioMidwest

  Weeks After Buying ReShape Medical for $38M, EnteroMedics Bags $61M

  EnteroMedics recently filed with the SEC that it had raised $61M in a new equity financing round. There were 13 anonymous investors.

  October 19, 2017

   · 

  3 min read

   · 

  Mark Terry